Atopic dermatitis: Positive topline Phase 3 results announced for dupilumab

Regeneron Pharmaceuticals, Inc. and Sanofi have announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary...